Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Pelak, DMJ; Hummer, A; Hug, PE; Töpfer, S; Birgit, Flechl, I; Mozes, P; Fossati, PP; Fussl, C; Surböck, B; Hainfellner, PJ; Wolfsberger, PS; Purkart, TU; Calabek-Wohinz, B; Mumot, M; Stock, PM; Lütgendorf-Caucig, C.
Patient-reported outcomes, neurocognitive functioning and oncologic results of pencil-beam-scanning proton beam therapy for CNS WHO G2 and G3 IDH1-mutant diffuse adult glioma: A single institution experience.
Int J Radiat Oncol Biol Phys. 2025; Doi: 10.1016/j.ijrobp.2025.10.025
PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Urbanic Purkart Tadeja

Wolfsberger Stefan

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

INTRODUCTION: Patients with IDH-mutant diffuse glioma achieve long survival after chemoradiotherapy. Proton beam therapy (PBT) can be used for this group to potentially reduce the late neurologic and cognitive complications. In the present study we analyzed the patient-reported outcomes (PROs), objective neurocognitive (NC) functioning and oncologic results of CNS-WHO G2 and G3 diffuse adult glioma treated with PBT in our institution. MATERIAL AND METHOD: This prospective observational study included 30 patients with IDH1/2-mutant CNS-WHO G2 and G3 astrocytoma and oligodendroglioma treated with pencil beam scanning PBT between 2017 and 2021. The total dose was 54.04 Gy (RBE)/28 fractions for G2 and 60 Gy (RBE)/30 fractions for G3 disease. PROs and NC testing were performed at baseline, end of treatment (EOT) 3, 6 and 12 months post EOT and afterwards annually. PROs included quality of life (QoL) questionnaires (EORTC QLQ-C30 and EORTC QLQ-BN20) and NC tests included Hopkins verbal learning test - revised, trail making test and controlled oral word association (COWA). RESULTS: The median follow-up was 62.5 months (range: 33.8 - 85.6). In QoL analysis, significant trends towards fewer symptoms were seen for future uncertainty (ß = -0.14, p = 0.036) and constipation (ß = -0.18, p = 0.005); the latter temporarily coinciding with completion of chemotherapy. As for NC scales, the results of COWA verbal fluency testing showed a significant longitudinal improvement (ß = 0.07, p < 0.001). Other QoL and NC scales showed unchanged status over time. The estimated 5-year progression-free and overall survival were 65.8% and 89.7%, respectively. The presence of MGMT promoter methylation corresponded to reduced risk of progression (HR = 0.24, 95%CI: 0.06-0.9, p = 0.034) and death (HR = 0.05, 95%CI: 0.005-0.56, p = 0.015). CONCLUSION: Proton therapy is a safe and effective treatment for IDH1/2-mutant diffuse glioma with no apparent detrimental effect on QoL and neurocognitive functioning in this prospective cohort.

© Med Uni Graz • Imprint